Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants-Reference-Cited by-同舟云学术

Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants

Published:2022-06-11 Issue:10 Volume:94 Page:5038-5043
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:Journal of Medical Virology

Author:

Brehm Thomas Theo¹²,Pfefferle Susanne²³⁴,von Possel Ronald³⁵,Karolyi Mario⁶,Zoufaly Alexander⁶⁷,Wichmann Dominic⁸,Kobbe Robin¹,Emmerich Petra³⁵,Nörz Dominik⁴,Aepfelbacher Martin⁴,Schulze zur Wiesch Julian¹²,Addo Marylyn M.¹²⁹,Schmiedel Stefan¹²,Lütgehetmann Marc²⁴

Affiliation:

1. Division of Infectious Diseases, I. Department of Internal Medicine University Medical Center Hamburg‐Eppendorf Hamburg Germany

2. German Center for Infection Research (DZIF) Partner Site Hamburg‐Lübeck‐Borstel Riems Hamburg Germany

3. Bernhard Nocht Institute for Tropical Medicine Hamburg Germany

4. Center for Diagnostics, Institute of Medical Microbiology, Virology and Hygiene University Medical Center Hamburg‐Eppendorf Hamburg Germany

5. Department of Tropical Medicine and Infectious Diseases Center of Internal Medicine II, University of Rostock Rostock Germany

6. Department of Medicine 4 Klinik Favoriten Vienna Austria

7. Faculty of Medicine, Sigmund Freud University Vienna Austria

8. Department of Intensive Care Medicine University Medical Center Hamburg‐Eppendorf Hamburg Germany

9. Institute for Infection Research and Vaccine Development University Medical Center Hamburg‐Eppendorf Hamburg Germany

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.27916

Reference16 articles.

1. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic

2. Omicron severity: milder but not mild

3. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

4. The omicron variant is highly resistant against antibody‐mediated neutralization: implications for control of the COVID‐19 pandemic;Hoffmann M;Cell,2021

5. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study;Microbiology Spectrum;2023-02-14

2. Casivirimab/Imdevimab Effect on COVID-19 Outcome and Reinfection in a Real-World SARS-COV-2 Variant Transition Period Setting;Monoclonal Antibodies in Immunodiagnosis and Immunotherapy;2023-02-01

3. Guía práctica de las nuevas alternativas terapéuticas frente a SARS-CoV-2 en pacientes con inmunomoduladores de uso frecuente en dermatología;Actas Dermo-Sifiliográficas;2023-01

4. [Translated article] Practical Guide to New Treatments for SARS-CoV-2 Infection in Dermatology Patients Being Treated With Common Immunomodulators;Actas Dermo-Sifiliográficas;2023-01

5. The clinical effectiveness of REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants;PLOS ONE;2022-12-02